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Objective: The aim of the Acromegaly Consensus Group was to revise and update the 
consensus on diagnosis and treatment of acromegaly comorbidities last published in 2013.  
Participants: The Consensus Group, convened by 11 Steering Committee members, 
consisted of 45 experts in the medical and surgical management of acromegaly. The authors 
received no corporate funding or remuneration. 
Evidence: This evidence-based Consensus was developed using the Grading of 
Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe 
both the strength of recommendations and the quality of evidence following critical discussion of 
the current literature on the diagnosis and treatment of acromegaly comorbidities. 
Consensus Process: Acromegaly Consensus Group participants conducted comprehensive 
literature searches for English-language papers on selected topics, reviewed brief presentations 
on each topic, and discussed current practice and recommendations in breakout groups. 
Consensus recommendations were developed based on all presentations and discussions. 
Members of the Scientific Committee graded the quality of the supporting evidence and the 
consensus recommendations using the GRADE system. 
Conclusions: Evid nce-based approach consensus recommendations address important 
clinical issues regarding multidisciplinary management of acromegaly-related cardiovascular, 
endocrine, metabolic, and oncologic comorbidities, sleep apnea, and bone and joint disorders and 























The Acromegaly Consensus Group presents evidence-based recommendations for optimizing 






















Excess levels of circulating growth hormone (GH) and insulin-like growth factor (IGF)-I in 
acromegaly have deleterious effects on a wide range of tissues and physiologic processes (1,2). 
Patients commonly experience abnormal growth of bone and soft tissue (3,4) and have 
dysregulated glucose metabolism (5,6) with increased risk for cardiovascular disease (7), all of 
which may impact mortality risk (8). Treatment of patients with acromegaly is aimed at 
controlling excess GH and/or IGF-I levels, but signs and symptoms of the disease often persist 
despite achievement of biochemical control (1,9,10). The diagnosis and optimal management of 
acromegaly comorbidities is critical to ensuring the best long-term outcome for this chronic 
illness. 
The Acromegaly Consensus Group published the first set of recommendations on diagnosis 
and treatment of disease complications in 2003 (11), and updated them in 2013 (12). In concert 
with development of new disease management protocols (9), and the conceptualization of the 
Pituitary Tumor Center of Excellence (13), investigators have increasingly been focusing on 
defining and optimizing management strategies for acromegaly comorbidities and disease-related 
sequelae. In June 2018, 45 experts in acromegaly management reviewed the literature and 
critically assessed new research findings and changes in clinical practice standards and clinical 
opinion since the 2013 consensus publication. Discussions focused on: cardiovascular, 
endocrine, metabolic, and oncologic comorbidities, sleep apnea, and bone and joint disorders, as 
well as the impact of these disease sequelae on quality of life (QoL) and mortality. Updated 
consensus recommendations on diagnosis and treatment of acromegaly comorbidities were 





















system (GRADE; Table 1) (14,15) and key consensus recommendations are presented in Table 
2. 
 
Materials and Methods 
The process for development of consensus recommendations by Acromegaly Consensus 
Group participants before and during the meeting has been described (9). Briefly, participants 
were assigned specific topics related to acromegaly complications and conducted comprehensive 
literature searches for English-language papers published between March 2011 and May 2018. 
Search terms included “acromegaly” and “comorbidities” as well as terms associated with each 
respective topic covered. After brief presentations to the entire group on each topic, breakout 
groups discussed current practice and recommendations, and a summary of the findings reported 
back to the entire group. Consensus recommendations were developed based on all presentations 
and discussions and all participants voted on each recommendation. After the meeting, members 
of the Scientific Committee graded both the quality of the supporting evidence and the consensus 
recommendations using the GRADE system (Table 1). Evidence was graded by strength as very 
low quality (VLQ), low quality (LQ), moderate quality (MQ), or high quality (HQ). 
Recommendations were classified as discretionary (DR) or strong (SR). 
 
Cardiovascular Disease 
Although cardiovascular morbidity has improved significantly, cardiovascular disease is still an 
important cause of mortality among patients with acromegaly, despite the recent shift to cancer 
as the leading cause of mortality (16-18) and rates among those with well-controlled acromegaly 





















much of this shift is due to improved treatment of acromegaly and its comorbidities versus 
overall improved cardiac care and more stringent cardiovascular risk management; further 
studies are needed to distinguish between these factors. 
Hypertension is a major contributor to cardiovascular mortality in acromegaly (HQ) (8), but 
recent reports have indicated the positive impact of effective medical control. Prevalence is 
estimated at approximately 30% and may be as high as 60% in some series (19,20), with 
markedly higher rates seen in patients with biochemically uncontrolled acromegaly (MQ) (7,21). 
Excess GH leads to insulin resistance, endothelial dysfunction, and increased sodium and water 
retention resulting in increased plasma volume and leading to hypertension (22), but these effects 
may not be fully reversible, and hypertension may persist despite biochemical control of 
acromegaly (MQ) (23). Management of hypertension in acromegaly should be consistent with 
guidelines for the general population (SR). 
Arrhythmia is relatively uncommon (24), and, when present, is likely related to structural 
heart disease, particularly cardiomyopathy (LQ) (25). However, patients may exhibit a prolonged 
QT interval (MQ) (26). Treatment selection for acromegaly should therefore consider potential 
effects on QT interval (SR). Study data suggest a possible risk of QT interval prolongation with 
pasireotide (27). Although the clinical relevance of this effect is unclear, monitoring prior to and 
during treatment is advisable (28). Retrospective data on octreotide/lanreotide in acromegaly 
patients do not suggest similar effects (27,29). Contributing risk from concomitant therapies that 
prolong QT interval should also be evaluated (DR). 
As subclinical cardiomyopathy may be present (30), baseline echocardiogram is indicated 
(SR). Although prevalence of left ventricular hypertrophy (LVH) may be lower than earlier 





















of damage by echocardiography (LQ) (31), assessment of changes in cardiac structure is 
important for long-term management. Magnetic resonance imaging is not required to determine 
the most appropriate treatment (DR). 
Heart failure occurs uncommonly in acromegaly, and is likely influenced by risk factors such 
as disease duration and severity, the presence of hypertension and diabetes mellitus, and family 
history (MQ) (32). The significance of cardiac valve disease with regurgitation specific to 
acromegaly is difficult to assess as tricuspid insufficiency is relatively common in the general 
population and other factors, such as hypertension, likely influence its risk (LQ). 
Prevalence of ischemic heart disease is not increased due to acromegaly per se (33,34). Risk 
is likely more related to common risk factors such as hypertension, hyperlipidemia, disturbed 
glucose homeostasis, and smoking (LQ). 
Biochemical control of acromegaly with SRLs and pegvisomant reduces LVH progression 
and improves other markers of structural cardiac dysfunction, including left ventricular ejection 
fraction (MQ) (35,36). By contrast, the incidence of valvular abnormalities and the risk for 
further progression of valvulopathy remain unchanged (LQ) (37). Data are reassuring regarding 
the risk for cardiac valve disease in patients with acromegaly treated with cabergoline (38) but 
additional studies are needed (VLQ). 
 
Endocrine and Metabolic Disorders 
Diabetes mellitus 
Impaired glucose tolerance and diabetes mellitus (DM) are the most frequent metabolic 





















expected to rise further as the prevalence of DM continues to increase in the general population 
(VLQ). 
Acromegaly patients develop insulin resistance due to GH excess, and in those with 
longstanding disease, insulin insufficiency with impaired glucose tolerance may also occur (MQ) 
(41). Accordingly, if antidiabetic therapy is necessary, DM should be managed as for the general 
population and metformin considered as first-line therapy (SR). Tighter HbA1c control is 
recommended for younger patients (DR). Glucagon-like peptide (GLP)-1 agonists and dipeptidyl 
peptidase (DPP-4) inhibitors are largely untested and should be considered as second-line 
treatment on an individualized basis (DR). Sodium-glucose cotransporter (SGLT)-2 inhibitors 
may be a less favorable option due to increased risk for ketoacidosis in patients with acromegaly 
(DR) (42). 
Importantly, the presence of DM influences the choice of acromegaly medical therapy (MQ). 
Octreotide and lanreotide generally have a neutral effect on glucose control (MQ) (43), although 
monitoring of glycemia is advisable (SR). Pasireotide is not recommended in patients with 
uncontrolled DM due to the high risk for developing hyperglycemia (SR) (9,44,45). The decision 
to continue pasireotide in a patient who develops hyperglycemia should be individualized. If the 
benefits of continuing pasireotide outweigh hyperglycemic risk, data from healthy subjects 
suggest that treatment with concomitant GLP-1 agonists or DPP-4 inhibitors may be useful in 
minimizing the hyperglycemic effect (DR) (46), but real-world applicability to acromegaly 
patients on long-term pasireotide remains unknown. Pegvisomant treatment improves glucose 
metabolism in acromegaly patients (47,48) and should be considered in patients with partial or 





















Considering the negative effects of disturbed glucose homeostasis on patient outcomes, 
including mortality risk (MQ) (8,49), all acromegaly patients should be screened for dysglycemia 
at diagnosis and during follow-up by fasting blood glucose or oral glucose tolerance and HbA1c 
assessment (SR). Consequent therapy for hyperglycemia is mandatory for optimizing outcome. 
 
Hypopituitarism 
Hypogonadism is detected in approximately 50% of patients and results from tumor mass effect, 
and/or concomitant hyperprolactinemia (MQ) (50,51). Hypogonadism may compromise sexual 
function, fertility, body composition, well-being, and bone health; proper assessment and 
adequate replacement of hormonal deficits is recommended (SR) (10). As acromegaly can lead 
to decreased sex hormone binding globulin (SHBG) levels (LQ) (52), free testosterone should be 
measured or free testosterone indices should be calculated to assess gonadal function in males 
with active acromegaly to avoid overdiagnosis of hypogonadism (DR). 
Gonadal steroids significantly modulate the GH/IGF system. Testosterone enhances action of 
GH; estrogens, when taken orally, reduces hepatic IGF-I production, thereby indirectly 
attenuating GH action  (LQ) (53). Therefore, the choice and route of gonadal steroid replacement 
can significantly affect underlying acromegaly disease activity. Selective estrogen receptor 
modulators (SERMs) are synthetic estrogen-like compounds with tissue-specific agonist and 
antagonist actions. As such, they may be used to modulate disease activity in acromegaly, 
improving gonadal activity via central antiestrogen action while also reducing hepatic IGF-I 
production via estrogen agonist action (VLQ) (54). 
Insufficient replacement of other pituitary hormone deficiencies, such as in central 





















dyslipidemia and increased cardiovascular risk (LQ) (55,56). High doses of glucocorticoid 
replacement have also been associated with increased mortality risk (VLQ) (57). However, as the 
GH/IGF-I axis affects cortisol metabolism (58), careful assessment of hormone replacement 
strategies is recommended (SR) (59). 
Conventional radiation therapy increases risk for hypopituitarism and contributes to higher 
mortality rates (MQ) (57). These patients require careful long-term monitoring for the 
development of hormonal deficits. It is as yet unknown whether modern radiosurgical 
approaches are associated with a reduced impact on mortality compared with conventional 
radiotherapy (VLQ). 
 
Obstructive sleep apnea 
Obstructive sleep apnea (OSA) is detected in up to 80% of newly diagnosed acromegaly patients 
(HQ) (40,60-62), and results mainly from pharyngeal soft tissue swelling characteristic of 
acromegaly (MQ) (63,64). OSA has well-described adverse effects on the cardiovascular system, 
and is an independent risk factor for ischemic heart disease, arrhythmia, cardiomyopathy, and 
other cardiovascular disorders (MQ). 
Every patient should undergo careful assessment for OSA at diagnosis of acromegaly; this 
includes a thorough history, questioning of spouse/partner, and potentially use of a sleep 
questionnaire, such as the Epworth sleepiness scale (SR) (65). If OSA is suspected on screening, 
polysomnography could be considered before initial acromegaly surgery. In patients with severe 
pharyngeal swelling, polysomnography may be performed and pre-operative medical treatment 





















Effective treatment of acromegaly, with reduction of GH/IGF-I, and concomitant reduction 
in soft tissue swelling, may significantly improve OSA. Nevertheless, because OSA may persist 
or worsen despite appropriate acromegaly therapy (MQ) (61,66,67), post-treatment evaluation is 
essential and regular monitoring recommended. Continuous positive airway pressure (CPAP) 
with a specially fitted mask may be necessary for patients with atypical facial morphometry due 




Prevalence of dyslipidemia in acromegaly is generally similar to that of the general population. 
Lipoprotein(a) may be elevated while HDL cholesterol may be lower (VLQ) (68,69), but the 
clinical significance of these findings is unclear. Diagnosis, treatment, and management of 
dyslipidemia should follow guidelines for the general population (SR), with treatment goals and 
regimens accounting for presence of other metabolic comorbidities of acromegaly, such as 




Acromegaly is associated with specific GH- and IGF-I induced joint changes that increase the 
risk for arthropathy (HQ) (3,70,71). Cartilage hypertrophy and osteophyte formation contribute 
to joint space narrowing that may initially be reversible (VLQ) (3). Over time, however, joint 





















majority of patients even after long-term disease control (MQ) (72). Early diagnosis and 
treatment of acromegaly may therefore improve reversibility of arthropathy (SR). 
Arthropathy pain is one of the most prominent symptoms negatively affecting QoL in 
patients with acromegaly, and can result in significant deterioration of function over time (MQ) 
(73). Treatment of arthropathy should follow guidelines as for the general population (SR). 
However, clinical and radiological findings of acromegaly-associated arthropathy differ from 
those of primary osteoarthritis (74), and should be considered when selecting an intervention 
approach (DR). 
 
Carpal tunnel syndrome 
Carpal tunnel syndrome in acromegaly is caused by median nerve enlargement and resultant 
delayed conduction velocity that correlates with disease duration and IGF-I level (MQ) (75,76). 
Most patients show symptomatic improvement with acromegaly control, although increased 
nerve diameter may not be reversible despite treatment (LQ) (76,77). Depending on the severity 




Fractures of the vertebrae detected with vertebral morphometry, particularly of the thoracic 
spine, are highly prevalent in acromegaly patients with active disease, reported to affect up to 
60% of patients (HQ) (78,79). Estimates from available data suggest a 3-fold to 8-fold higher 
prevalence than in the general population, and a slight predominance in males vs females (LQ) 





















turnover and deterioration of cortical and trabecular bone structure (MQ) (80-83). Accordingly, 
fracture risk is highest in patients with long-standing active acromegaly. Biochemical control 
corrects bone turnover defects and protects against fracture risk (MQ) (81,84-86). Lumbar spine 
trabecular bone score, related to bone microarchitecture, provides information on bone strength 
independent of BMD (80). However, some patients with biochemically controlled acromegaly 
may still have a higher risk of vertebral fracture as a result of permanent or irreversible 
alterations in bone structure (MQ) (78,82,87). Notably, although prevalence of vertebral fracture 
is higher in eugonadal men with acromegaly than in healthy controls (78), hypogonadism is a 
significant independent risk factor for increased incidence and adverse outcome of fracture (MQ) 
(87) and androgen replacement therapy should be considered in hypogonadal men and estrogen 
substitution considered in postmenopausal women (SR).  
Because the presence of a vertebral fracture is a strong predictor of subsequent fractures, and 
because optimization of biochemical control as well as correction of other risk factors (eg, 
hypogonadism) may reduce these events (80), imaging studies to assess bone morphometry are 
suggested in all patients at diagnosis, regardless of disease status (SR), with follow-up studies 
repeated as appropriate to clinical disease activity, hypogonadism, and comorbid skeletal 
disorders (DR) (71). Bone mineral density is not a good reflection of bone quality in acromegaly, 
and may be normal as assessed on standard dual X-ray absorptiometry (MQ) (78,81,88-90). 
Further studies are needed to determine the role of vitamin D supplementation and bone-
























The raw incidence of cancer, specifically colon and thyroid, appears to be increased in patients 
with acromegaly (MQ) (91). However, intensity of screening can influence reported incidence 
rates and confound efforts to reduce cancer incidence through routine screening (LQ) (92). 
Excess GH and IGF-I have been linked to colon epithelial transformation and polyposis, 
respectively (LQ) (93,94). These observations would suggest that acromegaly patients undergo 
screening colonoscopy at diagnosis (DR), although there are no conclusive data linking 
screening frequency to colon cancer mortality rates (LQ) (95), and cancer-specific mortality rates 
in acromegaly are generally similar to those observed in the general population (MQ) (16). In 
addition, increased life expectancy of acromegaly patients has been associated with more deaths 
due to malignancies that are not normally related to GH/IGF-I excess. Thus, cancer incidence in 
acromegaly seems to be more related to age than to GH excess as observed in the general 
population (96). 
Current evidence does not support routine screening for thyroid cancer at acromegaly 
diagnosis (DR) (97,98). However, thyroid ultrasound and careful evaluation is recommended in 
those with palpable thyroid nodules and other risk factors for thyroid cancer, consistent with 
guideline recommendations for the general population (SR) (99).  
Follow-up and screening for all other cancers should be performed according to 
national/regional guidelines for the general population (SR). 
 
Impact of Comorbidities on Therapeutic Approaches 
GH levels directly reflect somatotroph tumor secretory activity and IGF-I levels reflect 





















related IGF-I levels remain cornerstone biochemical targets for acromegaly management (SR) 
(2).  
However, acromegaly has an adverse effect on QoL, largely due to musculoskeletal 
complications and persistent comorbidities (MQ) (100,101), and the economic burden of disease 
may further adversely affect QoL (LQ) (102). Although effective treatment of acromegaly may 
improve QoL, biochemical control does not necessarily correlate with clinical well-being and 
QoL impairments often persist despite biochemical control (MQ) (101,103). A patient-centered 
approach, accounting for biochemical parameters, comorbidities, treatment complications, and 
QoL measures, should all be considered in treatment decisions (SR) (102). Scoring systems such 
as SAGIT (104) and ACRODAT (105) are useful to assess overall disease activity and general 
and acromegaly-specific QoL instruments such as AcroQoL (106) can be helpful in identifying 
specific factors for follow-up (DR). When GH and IGF-I levels are discrepant, and when patients 
are only partially responsive to treatment, clinical factors, including disease-related symptoms, 
should be used to assess disease control and guide treatment decisions (SR) (9). 
 
Conclusions 
Recent advances in acromegaly disease control as well as improved management of 
comorbidities have led to lower mortality rates, approaching those of the general population. 
Integrated acromegaly management requires a personalized approach to treatment (SR) (107). 
Effective management of comorbidities should lead to further decreased morbidity and mortality 
and improved QoL (SR). Pituitary Tumor Centers of Excellence (13) provide multimodal 
management of both biochemical dysfunction and mass effects, as well as access to a wide range 





















approach appears effective in treating adverse comorbidities and is critical, as many patients with 
acromegaly will not achieve biochemical control and comorbidities may not remit even when 
full biochemical control is achieved (SR). 
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Table 1. Grading of Evidence and Recommendations 
 
Grading the evidence Grading the recommendations 
 Very low quality (VLQ): expert opinion 
supported by one or few small 
uncontrolled studies 
 Low quality (LQ): supported by large 
series of small uncontrolled studies 
 Moderate quality (MQ): supported by one 
or few large uncontrolled studies or meta-
analyses 
 High quality (HQ): supported by 
controlled studies or large series of large 
uncontrolled studies with sufficiently long 
follow-up 
 Discretionary recommendation (DR): 
based on VLQ or LQ evidence 
 Strong recommendation (SR): based on 
MQ or HQ evidence 




























Blood pressure measurement At baseline and every 6 months or upon 
change of antihypertensive treatment 
Echocardiography Annually, if abnormal 
ECG Annually, if abnormal 
Endocrine and Metabolic Disorders 
Epworth scale or sleep study Annually 
Before surgery if OSA is suspected 
Fasting blood glucose or OGTT Fasting blood glucose every 6 months, 
particularly in uncontrolled disease and 
during SRL therapy; HbA1c every 6 months 
if diabetes or prediabetes is present 
Total testosterone, SHBG, and PRL (males) Annually; consider testing free testosterone if 
there are doubts in interpretation of total 
testosterone 
LH, FSH, 17β-estradiol, and PRL (females) Annually, in pre-menopausal females with 
menstrual dysfunction and when pregnancy is 
desired 





















Serum 8-9 AM cortisol If central adrenal insufficiency is suspected; 
cosyntropin stimulation test if serum cortisol 
is low 
Musculoskeletal Disorders 
DXA Every 2 years particularly if 
osteopenia/osteoporosis is present 
Vertebral morphometry on thoracic x-ray, 
thoracic and lumbar spine x-ray 
Annually, particularly if history of vertebral 
fracture, decrease in BMD, kyphosis, 
symptoms of vertebral fracture, untreated 
hypogonadism, and no biochemical control of 
acromegaly 
Cancer 
Colonoscopy Every 10 years; more frequently if IGF-I 
remains persistently elevated or if abnormal 
colonoscopy or family history of colon cancer 
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